Agenus Inc (NAS:AGEN)
$ 15.71 0.58 (3.83%) Market Cap: 329.90 Mil Enterprise Value: 352.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

Agenus Inc To Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress Transcript

Jun 29, 2022 / 02:00PM GMT
Release Date Price: $40.04 (+10.87%)
Ethan Lovell

Good morning and good afternoon, and welcome to Agenus ESMO GI webcast. We're coming to you live from Barcelona, Spain where we're excited to share with you the remarkable botensilimab/balstilimab combination data we released earlier today in which Dr. Anthony El-Khoueiry presented at ESMO GI's opening session. I am Ethan Lovell, Agenus' Chief Communications Officer, and I'm glad you've been able to join us today.

Before we begin the formal presentation, however, I do need to provide our forward-looking statements disclosure. I'd like to remind you today that this webcast will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and time lines, including time lines for data release and partnership opportunities. These statements are subject to risks and uncertainties, and we refer you to our SEC filings for more details on these risks.

With that housekeeping out of the way, I'd like to invite Dr. Steven OâDay, Agenus' Chief Medical Officer, to the podium to provide some opening commentary Dr. O'Day?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot